Juan Manuel Saiz 🇪🇺

PMP® | Research Alliances & Innovation | Business Development | Advanced Therapies and Biomedicine | Connecting the dots from @CIMA_unav (formerly @CNTA_CIT)

[Juan Manuel Saiz 🇪🇺 @jmsaizPMP]

FDA oncology roundup: drugs, imaging agents and diagnostics gain approval
https://t.co/9w0XfPqERt a través de @PharmaTechFocus

[Juan Manuel Saiz 🇪🇺 @jmsaizPMP]

¿Qué sabemos de la relación entre alcohol, dieta mediterránea y salud? https://t.co/H4F8STMaK1

[Juan Manuel Saiz 🇪🇺 @jmsaizPMP]

Enfermedad hepática crónica en Europa: una crisis prevenible que pasa desapercibida https://t.co/eli6vwRCIw

[Juan Manuel Saiz 🇪🇺 @jmsaizPMP]

¿Por qué cada vez hay más alergias? https://t.co/UJk5YjuQG7

[Juan Manuel Saiz 🇪🇺 @jmsaizPMP]

Un nuevo tratamiento con virus busca frenar 3 tipos de tumores cerebrales en pacientes de hasta 25 años https://t.co/IxzsZxYaFl a través de @GacetadeSalud

[Juan Manuel Saiz 🇪🇺 @jmsaizPMP]

UK government bolsters antiviral supply for hantavirus
https://t.co/FGzNVOawS9 a través de @PharmaTechFocus

[Juan Manuel Saiz 🇪🇺 @jmsaizPMP]

Nonprofits join forces to debut marketplace for shelved CGTs https://t.co/3W311kLvzH

[Juan Manuel Saiz 🇪🇺 @jmsaizPMP]

Regulatory round-up: A month of key FDA approvals for cancer drugs
https://t.co/fKEb4IkJOp a través de @PharmaTechFocus

[Visegrád 24 @visegrad24]

Director-General of the World Health Organization (WHO) Tedros Ghebreyesus says he "expects more cases" of Hantavirus to be announced.

He says it’s due to the long time between the first case & when the outbreak was discovered. Ship passengers interacted closely in the meanwhile

[Juan Manuel Saiz 🇪🇺 @jmsaizPMP]

El Cima Universidad de Navarra obtiene la acreditación como Centro de Excelencia Severo Ochoa https://t.co/0VCO3UhLw1

[Juan Manuel Saiz 🇪🇺 @jmsaizPMP]

Switzerland’s biotech sector defies tough markets with record revenue https://t.co/VCTOEpQHN2

[Juan Manuel Saiz 🇪🇺 @jmsaizPMP]

UCB buys Candid Therapeutics for up to US$2.2bn to deepen autoimmune T-cell engager push https://t.co/VCTOEpQHN2

[Juan Manuel Saiz 🇪🇺 @jmsaizPMP]

Madrigal outlays $1bn for Arrowhead’s siRNA MASH asset
https://t.co/6oFv939V9b a través de @PharmaTechFocus

[Juan Manuel Saiz 🇪🇺 @jmsaizPMP]

This paper reviews the global Alzheimer’s disease (AD) drug development pipeline in 2026, tracking all active clinical trials and candidate therapies https://t.co/N72KcQReit

[Juan Manuel Saiz 🇪🇺 @jmsaizPMP]

Non-viral gene therapies emerge as key players amid viral safety bottlenecks
https://t.co/yQNEyGSxos a través de @PharmaTechFocus

[Juan Manuel Saiz 🇪🇺 @jmsaizPMP]

Parkinson’s disease: neuromodulation and the search for disease modification
https://t.co/B13d736JWs a través de @MedicalTechMag

[Juan Manuel Saiz 🇪🇺 @jmsaizPMP]

LEO Pharma to acquire gene therapy company Replay
https://t.co/jmeLyljmy9 a través de @PharmaTechFocus

[Juan Manuel Saiz 🇪🇺 @jmsaizPMP]

The slow march of clinical biomarkers to become surrogate endpoints
https://t.co/fTERvtAxog a través de @TrialsArena

[Juan Manuel Saiz 🇪🇺 @jmsaizPMP]

Describen por primera vez la actividad antitumoral de inhibidores RAS en colangiocarcinoma https://t.co/pJVBMgBaAL via @elconfidencial

[Juan Manuel Saiz 🇪🇺 @jmsaizPMP]

Regeneron's gene therapy is first to win FDA approval for genetic hearing loss https://t.co/6cG212Sb4n via @fwpharma